Abstract
Temozolomide (TMZ) has shown modest efficacy in the treatment of recurrent brain metastasis (BM). We designed a new regimen utilizing dose-intensified, protracted course of TMZ in combination with vinorelbine, a lipophilic large-spectrum agent, in an attempt to improve the efficacy of TMZ. This phase I study was conducted to establish the maximum tolerated dose (MTD) of vinorelbine for this combination. Patients with recurrent or progressive BM were eligible. Chemotherapy consisted of 28-day cycles with TMZ (150 mg/m2, days 1-7 and 15-21) and vinorelbine (days one and eight at escalating doses). The starting dose was 15 mg/m2, with increments of 5 mg/m2 for each cohort of 3-6 patients, until MTD was reached (30 mg/m2). A total of 21 patients were enrolled; the median age was 59 (41-77). The primary tumor was lung cancer in 13 patients (NSCLC in 10, SCLC in 3), breast in 6, renal in 1 and endometrial in 1. Vinorelbine dose was 15 mg/m2 in seven patients, 20 mg/m2 in five, 25 mg/m2 in four and 30 mg/m2 in six. Grades 3 and 4 neutropenia developed in six patients, lymphopenia in nine, and thrombocytopenia in six; other toxicities were rare. No dose-limiting toxicity was seen. Out of 18 evaluable patients 2 had a radiographic respo...Continue Reading
References
Feb 1, 1996·Anti-cancer Drugs·C Mouchard-DelmasM Wiczewski
Jun 1, 1997·American Journal of Clinical Oncology·M ColleoniP Manente
Nov 26, 1999·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·X QuantinJ L Pujol
Jun 23, 2000·British Journal of Cancer·R K Gregory, I E Smith
Mar 16, 2001·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G RobinetF Mornex
Apr 13, 2001·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C ChristodoulouUNKNOWN Hellenic Cooperative Oncology Group
Nov 23, 2001·Journal of Neuro-oncology·L E AbreyM G Malkin
Jan 12, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D BafaloukosP Kosmidis
May 25, 2002·Cancer Investigation·Giovanni BernardoRaffaella Palumbo
Aug 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D AntonadouN Throuvalas
Nov 29, 2002·Oncology·Javier CortesEmiliano Calvo
Apr 3, 2003·British Journal of Cancer·A W TolcherE K Rowinsky
May 24, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R DziadziuszkoUNKNOWN EORTC Lung Cancer Group
May 24, 2003·Cancer Chemotherapy and Pharmacology·Michela DonadioOscar Bertetto
Oct 3, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M J van den Bent
Apr 23, 2004·Current Neurology and Neuroscience Reports·Antonio Marcilio Padula Omuro, Lauren Eileen Abrey
Jun 9, 2004·Neurology·W WickM Weller
Sep 15, 2004·Neurology·Roelien H EntingLauren E Abrey
Jan 5, 2005·International Journal of Radiation Oncology, Biology, Physics·Eugènia VergerFrancesc Graus
Mar 5, 2005·The New England Journal of Medicine·Elizabeth HorstmannChristine Grady
Mar 5, 2005·The New England Journal of Medicine·Razelle Kurzrock, Robert S Benjamin
Citations
Sep 18, 2008·Cancer·Raffaele AddeoSalvatore Del Prete
Oct 9, 2008·Current Opinion in Oncology·Riccardo SoffiettiElisa Trevisan
Sep 26, 2007·Anti-cancer Drugs·Ioannis GounarisDennis Yiannakis
Dec 17, 2009·Current Opinion in Oncology·Serena Ricciardi, Filippo de Marinis
Aug 26, 2009·International Journal of Clinical Oncology·Tobias Walbert, Mark R Gilbert
Nov 3, 2006·Expert Review of Neurotherapeutics·Jan Drappatz, Patrick Y Wen
Nov 2, 2013·Expert Review of Neurotherapeutics·George Klironomos, Mark Bernstein
Jul 11, 2008·The Oncologist·Hans-Joachim Stemmler, Volker Heinemann
Aug 4, 2007·The Oncologist·April F Eichler, Jay S Loeffler
Oct 21, 2017·Oncotarget·Rimas V LukasRavi Salgia
Dec 17, 2009·Journal of Neuro-oncology·Farkhad Manapov
Aug 15, 2012·Cancer Chemotherapy and Pharmacology·Raffaele AddeoMichele Caraglia
Nov 28, 2013·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·M J Gil-GilS Villà
Jul 18, 2014·Expert Opinion on Pharmacotherapy·Cagatay ArslanKadri Altundag
Nov 8, 2007·Journal of Neuro-oncology·Fabio M IwamotoLauren E Abrey
Dec 4, 2009·Journal of Neuro-oncology·Mario AmmiratiSteven N Kalkanis
Jun 16, 2010·Cancer·Anna NiwińskaKatarzyna Pogoda
Mar 30, 2010·Expert Opinion on Pharmacotherapy·Cagatay ArslanKadri Altundag
Jun 27, 2008·Current Treatment Options in Neurology·April F Eichler, Scott R Plotkin
May 3, 2011·Expert Opinion on Investigational Drugs·Raffaele Addeo, Michele Caraglia
Dec 4, 2009·Journal of Neuro-oncology·Jeffrey J OlsonSteven N Kalkanis
Aug 3, 2013·Wiener klinische Wochenschrift·Marco Ronald HasslerChristine Marosi
Nov 4, 2016·Pharmaceutical Research·Ramakrishna SamalaQuentin R Smith
Jul 5, 2007·Neurosurgical Focus·Robert Cavaliere, David Schiff
Aug 2, 2008·Expert Opinion on Pharmacotherapy·Christos KosmasNikolaos Mylonakis
Sep 24, 2009·Pharmaceutical Research·Fancy C ThomasQuentin R Smith
Aug 27, 2015·Cancer·Lakshmi NayakPatrick Y Wen
Aug 6, 2013·Acta neurochirurgica·Gabriele SchackertMatthias Kirsch
Jun 14, 2008·Critical Reviews in Oncology/hematology·Alicia TosoniAlba A Brandes